Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;135(8):2831-2837.
doi: 10.1002/lary.32123. Epub 2025 Mar 18.

Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older

Molly O Meeker  1 , Ryan Ivancic  2 , Brad deSilva  2 , Laura A Matrka  2
Affiliations

Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older

Molly O Meeker et al. Laryngoscope. 2025 Aug.

Abstract

Objective: Gardasil vaccination has been effective as primary prevention and adjuvant therapy for recurrent respiratory papillomatosis (RRP). We present an update to our previous research reporting a significant increase in the intersurgical interval (ISI) after adjuvant Gardasil vaccination. Our objectives were: (1) to assess the durability of Gardasil as an adjuvant in RRP with longer-term follow-up and an expanded cohort, and (2) to better control for the use of other non-Gardasil adjuvant therapies.

Methods: A retrospective chart review of adult patients > 45 years diagnosed with RRP from 2008 to 2022 was conducted. Patients were considered vaccinated if they received at least two Gardasil doses.

Results: There were 51 total patients, 14 vaccinated and 37 unvaccinated. There was a significant increase in the ISI for the vaccinated group from 126 to 304 days (p = 0.0039), with 100.1 ± 47.3 months follow-up. Our previous study, performed at 49.7 ± 30.3 months follow-up, found an ISI of 494 days in the vaccinated group. Non-Gardasil adjuvant use was greater in the vaccinated group, but we found no significant effect of non-Gardasil adjuvant use on ISI in the unvaccinated group (p = 0.34).

Conclusions: Adjuvant Gardasil use in RRP patients > 45 years significantly increases the ISI, which supports findings from our previous study. However, the magnitude of this effect may wane with time, with the ISI remaining significant but downtrending from 494 to 304 days. This data raise the question of whether booster Gardasil dosing warrants investigation.

Keywords: benign lesions; laryngology; papillomatosis/recurrent respiratory papillomatosis.

PubMed Disclaimer

References

    1. C. S. Derkay and B. Wiatrak, “Recurrent Respiratory Papillomatosis: A Review,” Laryngoscope 118, no. 7 (2008): 1236–1247, https://doi.org/10.1097/MLG.0b013e31816a7135.
    1. M. J. Silverberg, P. Thorsen, H. Lindeberg, L. Ahdieh‐Grant, and K. V. Shah, “Clinical Course of Recurrent Respiratory Papillomatosis in Danish Children,” Archives of Otolaryngology—Head & Neck Surgery 130, no. 6 (2004): 711–716, https://doi.org/10.1001/archotol.130.6.711.
    1. J. P. Lindman, L. S. Lewis, N. Accortt, and B. J. Wiatrak, “Use of the Pediatric Quality of Life Inventory to Assess the Health‐Related Quality of Life in Children With Recurrent Respiratory Papillomatosis,” Annals of Otology, Rhinology, and Laryngology 114, no. 7 (2005): 499–503, https://doi.org/10.1177/000348940511400701.
    1. Y. Yiu, S. Fayson, H. Smith, and L. Matrka, “Implementation of Routine HPV Vaccination in the Management of Recurrent Respiratory Papillomatosis,” Annals of Otology, Rhinology, and Laryngology 128, no. 4 (2019): 309–315, https://doi.org/10.1177/0003489418821695.
    1. J. Balažic, A. Mašera, and M. Poljak, “Sudden Death Caused by Laryngeal Papillomatosis,” Acta Oto‐Laryngologica 117, no. 527 (1997): 111–113, https://doi.org/10.3109/00016489709124049.

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources